[Endolymphatic chemotherapy and immunocorrection in patients with kidney and bladder cancers].
Serniak. P S PS; Geev. Iu V IuV; Prilutskiĭ. A S AS
Key Findings
- Cancer patients showed reduced expression of certain lymphocyte surface markers and T‑cell receptors.
- reported quality of life and some immune parameters.",
Practical Outcomes
- Thymalin might have a mild immune‑support effect when given via an unusual inner‑ear route, but the study provides no clear dosage, safety, or protocol for healthy or non‑clinical use, so it isn’t a ready‑to‑apply strategy for most biohackers.
Summary
A small study gave a peptide called thymalin directly into the inner ear of kidney and bladder cancer patients and saw a slight boost in their immune health and quality of life, but the immune markers still didn’t look like those of healthy people, and the researchers say more work is needed.
Abstract
Immunological examination and endolymphatic treatment were performed in 44 patients with cancer of the kidney or urinary bladder. In the majority of patients lymphocytes of the peripheral blood demonstrated reduced expression of some differential antigens. Subpopulation of T-lymphocytes, expression of T-lymphocyte receptors got decreased in almost all the patients. Endolymphatic introduction of immunocorrective thymalin improved the patients' life quality, their immune status. However, the level and proportional expression of differential lymphocyte antigens following course polychemotherapy and immunocorrection in patients do not coincide with relevant parameters of healthy subjects. It is evident that further search for optimal treatment schemes is needed.
Study Information
pubmed
1994